For the Inventor, By the Inventor

Enter assignee name

Munich, Germany

Amgen Research (munich) Gmbh

USPTO Granted Patents = 75

Trademarks = 1

Forward Citations = 465

Loading Chart...

Loading Chart...

132 inventors (with patents filed for the assignee):

Tobias Raum (49 out of 60 patents)

Peter Kufer (48 out of 64 patents)

Patrick Hoffmann (37 out of 39 patents)

4. Doris Rau (23 out of 27 patents)

5. Ralf Lutterbüse (20 out of 26 patents)

6. Roman Kischel (18 out of 21 patents)

7. Claudia Blümel (16 out of 16 patents)

8. Elisabeth Nahrwold (13 out of 13 patents)

9. Gerhard Zugmaier (11 out of 12 patents)

10. Christoph Dahlhoff (11 out of 11 patents)

11. Andreas Wolf (10 out of 16 patents)

12. Dirk Nagorsen (10 out of 11 patents)

13. Matthias Klinger (9 out of 10 patents)

14. Susanne Mangold (8 out of 9 patents)

15. Jochen Pendzialek (8 out of 8 patents)

Core Competencies:

Bispecific Antibody Constructs

CD3 Engaging Antibodies

Cross-Species Antibodies

T Cell Engaging Antibodies

Binding Molecules

Nucleic Acids Encoding Antibodies

Cancer Treatment

Acute Lymphoblastic Leukemia

BCMA Targeting

EGFRVIII Binding

MUC17 Antibodies

PSMA Antibody Constructs

75 patents: Sort by Forward Citations

1. 12441796 - Antibody constructs for CDH19 and CD3 (2025-10-14),

2. 12435139 - Antibody constructs for DLL3 and CD3 (2025-10-07),

3. 12428491 - PSMA and CD3 bispecific T cell engaging antibody constructs (2025-09-30),

4. 12312412 - MAGEB2 binding constructs (2025-05-27),

5. 12304952 - Antibody constructs for DLL3 and CD3 (2025-05-20),

6. 12297292 - Antibody constructs for CDH19 and CD3 (2025-05-13),

7. 12281176 - Binding molecules for BCMA and CD3 (2025-04-21),

8. 12281175 - Binding molecules for BCMA and CD3 (2025-04-21),

9. 12281172 - Cross-species-specific PSMAxCD3 bispecific single chain antibody (2025-04-21),

10. 12258411 - Anti-CCR8 antibodies and uses thereof (2025-03-25),

11. 12258404 - Bispecific antibody construct directed to MUC17 and CD3 (2025-03-25),

12. 12152078 - Nucleic acids encoding anitbody constructs binding EGFR VIII and CD3 (2024-11-26),

13. 11987633 - Cross-species-specific single domain bispecific single chain antibody (2024-05-21),

14. 11926666 - Bispecific antibody constructs for CDH3 and CD3 (2024-03-12),

15. 11925684 - Compositions comprising cross-species-specific antibodies and uses thereof (2024-03-12),

Amgen Research (Munich) GmbH is a subsidiary of Amgen Inc., a global biotechnology company that develops innovative therapies for patients suffering from serious illnesses. In Munich, Germany, Amgen Research focuses on conducting cutting-edge research in various therapeutic areas, including oncology, neuroscience, and inflammation. Through their dedication to scientific excellence, Amgen Research strives to make meaningful contributions to advancing medical knowledge and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

75 Patents

#59 in W-8000 Munich

#780 in Germany

#9,625 in the World

Munich, Germany

Amgen Research (munich) Gmbh

Forward Citations = 465

132 inventors:

Tobias Raum (49 out of 60 patents)

Peter Kufer (48 out of 64 patents)

Patrick Hoffmann (37 out of 39 patents)

4. Doris Rau (23 out of 27 patents)

5. Ralf Lutterbüse (20 out of 26 patents)

Please report any incorrect information to support@idiyas.com

Loading…